Business Insider

China's Infliximab Market Investigation Report 2021-2025 - A Human-mouse Chimeric IgG1 Monoclonal Antibody Targeting Tumor Necrosis Factor (TNF-A)

DUBLIN, July 29, 2021 /PRNewswire/ -- The "Investigation Report on China's Infliximab Market 2021-2025" report has been added to ResearchAndMarkets.com's offering. Infliximab is a human-mouse chimeric ...
Medical Xpress

Amino Acid, Peptide, or Protein: Infliximab

Biosimilar competition is not consistently associated with lower out-of-pocket (OOP) costs for commercially insured outpatients, according to a study published online March 29 in JAMA Health Forum. A ...
Healio

Infliximab discontinuation links to relapse in patients with ulcerative colitis

Please provide your email address to receive an email when new articles are posted on . In a multicenter, open-label trial, researchers investigated the outcomes of discontinued infliximab use in ...
Healio

Infliximab bests cyclophosphamide as first-line treatment of severe Behçet’s syndrome

Please provide your email address to receive an email when new articles are posted on . Week-22 remission rates were 81% among patients using infliximab and 56% in those on cyclophosphamide. Mild to ...
Medscape

Vedolizumab Beats Infliximab as Second-Line Therapy for Ulcerative Colitis

BERLIN — Ulcerative colitis (UC) patients who fail on first-line therapy appear to have better outcomes with vedolizumab (Entyvio) than with infliximab, suggests EFFICACI, the first trial directly ...